We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

90 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 6

69% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 16

37% more capital invested

Capital invested by funds: $130M → $179M (+$48.6M)

36% more funds holding

Funds holding: 66 → 90 (+24)

0.02% more ownership

Funds ownership: 0.64% → 0.66% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

83% less call options, than puts

Call options by funds: $27K | Put options by funds: $156K

Holders
90
Holders Change
+24
Holders Change %
+36.36%
% of All Funds
2.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
30
Increased
27
Reduced
16
Closed
6
Calls
$27K
Puts
$156K
Net Calls
-$129K
Net Calls Change
-$34K

Top Buyers

1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.59M
2
AL
AJO LP
Pennsylvania
+$1.7M
3
Millennium Management
Millennium Management
New York
+$1.49M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.47M
5
VIA
Vident Investment Advisory
Georgia
+$1.22M

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$5.09M
2
BI
BVF Inc
California
-$2.11M
3
OFM
Omega Fund Management
Massachusetts
-$1.74M
4
SFM
Sphera Funds Management
Israel
-$1.16M
5
EI
EAM Investors
California
-$348K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
76
Legal & General Group
United Kingdom
$50K +$8.37K +18 +28%
AIP
77
Ameritas Investment Partners
Nebraska
$23K – – –
Federated Hermes
78
Federated Hermes
Pennsylvania
$21K +$16.3K +35 New
DCM
79
Delpha Capital Management
New York
$18K +$13.5K +29 New
RBC
80
Roble Belko & Company
Pennsylvania
$16K +$12.1K +26 New
CHP
81
Cable Hill Partners
Oregon
$15K – – –
UBS Group
82
UBS Group
Switzerland
$12K -$13.9K -30 -61%
PCM
83
Prelude Capital Management
New York
$10K +$7.44K +16 New
CG
84
Cutler Group
California
$6K +$930 +2 +22%
RA
85
Royce & Associates
New York
$6K +$4.18K +9 New
FMA
86
FNY Managed Accounts
New York
$6K +$5.11K +11 New
MAM
87
Meeder Asset Management
Ohio
$6K +$5.11K +11 New
Citigroup
88
Citigroup
New York
$2K +$1.4K +3 +300%
Royal Bank of Canada
89
Royal Bank of Canada
Ontario, Canada
$1K -$17.2K -37 -95%
Walleye Trading
90
Walleye Trading
New York
$162 +$125K +269 New
PAM
91
Panagora Asset Management
Massachusetts
– -$214K -464 Closed
NFA
92
Nationwide Fund Advisors
Ohio
– -$111K -241 Closed
MWNA
93
Marshall Wace North America
New York
– -$103K -214 Closed
Balyasny Asset Management
94
Balyasny Asset Management
Illinois
– -$69K -150 Closed
TRCT
95
Tower Research Capital (TRC)
New York
– -$24K -52 Closed
SEI Investments
96
SEI Investments
Pennsylvania
– -$2.79K -6 Closed
1 2 3
4

PVLA Hedge Fund Activity: Q4 2017 in Review

90 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2017, worth a combined $179M — up 37% from $130M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PVLA positions and 6 closed out — a net gain of 24 holders — while 27 added to existing stakes and 16 trimmed.

The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $2.59M. The largest seller was Tekla Capital Management, cutting an estimated $5.09M.

  • 90 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2017, up from 66 in Q3 2017.
  • Funds reported $179M of Palvella Therapeutics stock for Q4 2017, up 37% quarter-over-quarter.
  • 30 funds opened new Palvella Therapeutics positions in Q4 2017 and 6 closed out, a net change of +24 holders.
  • The largest Palvella Therapeutics buyer in Q4 2017 was Arrowstreet Capital, an estimated $2.59M added.
  • The largest Palvella Therapeutics seller in Q4 2017 was Tekla Capital Management, an estimated $5.09M sold.

Based on aggregated 13F filings for Q4 2017.